[HTML][HTML] Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial
MR Gilbert, M Wang, KD Aldape, R Stupp… - Journal of clinical …, 2013 - ncbi.nlm.nih.gov
Journal of clinical oncology, 2013•ncbi.nlm.nih.gov
Purpose Radiotherapy with concomitant and adjuvant temozolomide is the standard of care
for newly diagnosed glioblastoma (GBM). O 6-methylguanine-DNA methyltransferase
(MGMT) methylation status may be an important determinant of treatment response. Dose-
dense (DD) temozolomide results in prolonged depletion of MGMT in blood mononuclear
cells and possibly in tumor. This trial tested whether DD temozolomide improves overall
survival (OS) or progression-free survival (PFS) in patients with newly diagnosed GBM.
for newly diagnosed glioblastoma (GBM). O 6-methylguanine-DNA methyltransferase
(MGMT) methylation status may be an important determinant of treatment response. Dose-
dense (DD) temozolomide results in prolonged depletion of MGMT in blood mononuclear
cells and possibly in tumor. This trial tested whether DD temozolomide improves overall
survival (OS) or progression-free survival (PFS) in patients with newly diagnosed GBM.
Abstract
Purpose
Radiotherapy with concomitant and adjuvant temozolomide is the standard of care for newly diagnosed glioblastoma (GBM). O 6-methylguanine-DNA methyltransferase (MGMT) methylation status may be an important determinant of treatment response. Dose-dense (DD) temozolomide results in prolonged depletion of MGMT in blood mononuclear cells and possibly in tumor. This trial tested whether DD temozolomide improves overall survival (OS) or progression-free survival (PFS) in patients with newly diagnosed GBM.
ncbi.nlm.nih.gov